Hospital Acquired Infection Treatment

Hospital Acquired Infection Treatment

Global Hospital Acquired Infection Treatment Market to Reach $40.9 Billion by 2030
The global market for Hospital Acquired Infection Treatment estimated at US$33.9 Billion in the year 2023, is expected to reach US$40.9 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2023-2030. Urinary Tract Infections Treatment, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$28.6 Billion by the end of the analysis period. Growth in the Ventilator-Associated Pneumonia Treatment segment is estimated at 2.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $10.1 Billion, While China is Forecast to Grow at 2.5% CAGR
The Hospital Acquired Infection Treatment market in the U.S. is estimated at US$10.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.3 Billion by the year 2030 trailing a CAGR of 2.5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 2.3% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories, Inc.
• Aridis Pharmaceuticals, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Cepheid, Inc.
• Cipla Ltd.
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Pfizer, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.